A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs DS-8500 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Jun 2017 Biomarkers information updated
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.